CClinicalTrials.gg
Active, not recruitingNCT06748755Updated Dec 27, 2024

A Comparative Analysis of Ultrasound's Accuracy in Diagnosing HC Using Histopathology as Gold Standard

An observational study in Hepatocellular Carcinoma, sponsored by Superior University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Superior University · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
90
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The study aims to evaluate the accuracy of ultrasound in diagnosing hepatocellular carcinoma (HCC), using histopathology as the gold standard. It addresses HCC's high global incidence and the utility of ultrasound as a non-invasive, cost-effective screening tool. Despite ultrasound's accessibility, its diagnostic limitations necessitate further investigation to improve clinical outcomes.

02

Conditions studied

  • Hepatocellular Carcinoma
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's enrollment of 90 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Superior University is the lead sponsor of 242 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

aim is to check the accuracy of Ultrasound's in Diagnosing Hepatocellular Carcinoma Using Histopathology as Gold Standard

Inclusion criteria

  • Clinically suspected liver cancer patients undergoing ultrasound examination.
  • Patients undergoing histopathological examination (liver biopsy or resection) for definitive diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of liver cancer treatment or inadequate data."
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
90 participants (actual)
Patient registry
No

Interventions

  • RadiationGroup 1

    To determine the sensitivity of ultrasound in detecting HCC

06

What researchers measure

Primary outcomes

  1. ultrasound

    Sensitivity and Specificity analysis of Ultrasound as diagnostic tool, with histopathology as gold standard.

    Time frame: 12 Months

07

Study locations

1 site
  • Medcare International Hospital
    Gujrānwāla, Punjab, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06748755
Lead sponsor
Superior University
Responsible party
Muhammad Naveed Babur (Principal Investigator, Superior University) — Principal investigator
First posted
Dec 27, 2024
Start date
Mar 1, 2024
Primary completion
Sep 1, 2024
Completion
Feb 20, 2025 (estimated)
Last update
Dec 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion